GALT Richard A Zordani JR. buys $6K worth of shares
Aug 26, 2024, 12:34 PM
-1.11%
What does GALT do
Galectin Therapeutics, Inc., based in Norcross, Georgia, focuses on developing therapies targeting galectin proteins for diseases such as fibrosis, skin conditions, and cancer, employing 12 people since its 2002 IPO. Their leading drug candidate, belapectin, a galectin-3 inhibitor, is currently under a Phase IIb/III NAVIGATE trial for treating liver conditions in NASH patients.
Richard A Zordani JR. bought 2,759 shares of GALT on 23 August at $2.30 per share, worth a total of $6K. They now own 32,083 GALT shares, or a 9% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.